The art of talking about risks with our patients https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ

• The art of talking about risks with our patients | RheumNow

The age old question in #inflammatory #arthritis Should you cycle within TNFi class or move on to another MOA in #PsA #psoriatic #arthritis Better retention to go to a IL17i vs another TNFi in observational study comparing the 2 POS0266 #EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9

• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1
• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1

Can you predict which pts with #PsA #psoriatic #arthritis Will respond to #TNFi #Rx? Well, 🤔 maybe Needs validation and an easy reliable inexpensive biomarker! #EULAR2024 @RheumNow @eular_org POS0992 https://t.co/Ce92561AMO

• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1
• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1

Another option for Knee Oa management? Wearable transcutaneous nerve stimulation (W-TENS) reduces the need for surgery. #EULAR2024 @rheumnow abst#POS1072 https://t.co/flcfrCrY2X

• https://twitter.com/bella_mehta/status/1801567808637063266/photo/1

Look out for multimorbidity in rheumatoid arthritis. McInnes I #EULAR2024 @RheumNow https://t.co/kgshkNcyLn

• https://twitter.com/synovialjoints/status/1801565932709360119/photo/1

#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly

• EULAR 2024 Daily Recap: Days 1 & 2
• https://twitter.com/Yuz6Yusof/status/1801555153968882024/photo/1

#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM

• https://twitter.com/Yuz6Yusof/status/1801553211758633253/photo/1
• https://twitter.com/Yuz6Yusof/status/1801553211758633253/photo/1

Infrapatellar fat pad morphology- mainly volume on MRI associated progostication in knee #OA - structural changes! using OAI data #EULAR2024 abst#OP0292 @rheumnow

OP0162 looks at mortality in 21277 seropositive and seronegative #RA 5-year mortality risk in both groups decreased over time but is higher in seropositive vs negative Sex-specific analysis reveals serological status in women did not affect mortality risk @RheumNow #EULAR2024

#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc

• https://twitter.com/Yuz6Yusof/status/1801548527299867135/photo/1

➡️OP0127- Can we predict who will get persistently active disease in people with palindromic rheumatism (PR)? 📊Cohort of 161 PR ❗️Predictive factors: Female gender, CCP, RF, >40yo, smoking & interval between flares of <1m ➡️ may be used to risk stratify @RheumNow #EULAR2024

beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0

• https://twitter.com/drpnash/status/1801547448709414948/photo/1

Différent stages of RA with disease progression. McInnes M #EULAR2024 @RheumNow https://t.co/iKpggGYU0k

• https://twitter.com/synovialjoints/status/1801546516101742753/photo/1

#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z

• https://twitter.com/Yuz6Yusof/status/1801545366212411600/photo/1
• https://twitter.com/Yuz6Yusof/status/1801545366212411600/photo/1